Edgewise sells sevasemten to Servier for $1.55B upfront, plus up to $1.1B milestones

Edgewise Therapeutics, Inc.

$1.55B upfront cash; potential $1.1B in regulatory and commercial milestones totaling up to $2.65B.
Edgewise to focus on cardiovascular pipeline (EDG-7500, EDG-15400, EDG-003).
Upfront proceeds fully fund EDG-7500 development through potential approval.
On track to report 12-week CIRRUS-HCM Part D data in Q2 2026.
Transaction expected to close Q3 2026, subject to HSR and customary conditions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Edgewise Therapeutics, Inc. entered into Asset Purchase Agreement with Servier Pharmaceuticals LLC and Les Laboratoires Servier valued at $1.55 billion in cash at closing, plus potential milestone payments up to $1.1 billion (effective 2026-05-31).

Action: entry
Agreement: asset purchase
Counterparty: Servier Pharmaceuticals LLC and Les Laboratoires Servier
Value: $1.55 billion in cash at closing, plus potential milestone payments up to $1.1 billion
Effective: 2026-05-31

Exact text from the filing

On June 1, 2026, Edgewise Therapeutics, Inc., (the “Company”) announced its entry into an Asset Purchase Agreement (the “Agreement”) with Servier Pharmaceuticals LLC and Les Laboratoires Servier (together, the “Buyers”) on May 31, 2026.

View on SEC.gov

Browse all material agreements →

Edgewise Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-249951

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.